Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Portfolio Pulse from
Jaguar Health's subsidiary Napo Pharmaceuticals has secured an FDA Type C Meeting in Q2 2025 to discuss positive Phase 3 OnTarget study results for crofelemer in breast cancer patients. The study showed significant diarrhea management potential for patients undergoing targeted cancer therapies, with 183 of 287 trial participants being breast cancer patients.
March 27, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive Phase 3 study results and upcoming FDA meeting could position crofelemer as a novel treatment for managing diarrhea in breast cancer patients receiving targeted therapies.
Positive clinical trial results, FDA meeting, and potential new market indication could drive investor interest and stock price appreciation.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100